martes, 4 de agosto de 2020

DOJ probes Sanofi, GSK over possible carcinogen in Zantac

DOJ probes Sanofi, GSK over possible carcinogen in Zantac

Daily Recap

STAT Plus: Justice Department probes Sanofi and GlaxoSmithKline over possible carcinogen in Zantac pills

By ED SILVERMAN


DREW ANGERER/GETTY IMAGES
The theory is the drugs should not have been reimbursed by the government if they were unapproved, misbranded or adulterated, an expert said.

No hay comentarios: